BeiGene Ltd.

316.93-4.80-1.49%Vol 304.47K1Y Perf 35.97%
Jul 23rd, 2021 16:00 DELAYED
BID317.32 ASK324.00
Open315.61 Previous Close321.73
Pre-Market- After-Market316.93
 - -  - -%
Target Price
399.66 
Analyst Rating
Moderate Buy 1.77
Potential %
26.10 
Finscreener Ranking
★★★★+     55.61
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     48.04
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★+     55.27
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap29.28B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
61.02 
Earnings Date
5th Aug 2021

Today's Price Range

309.39318.92

52W Range

204.17388.97

5 Year PE Ratio Range

-36.70-17.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.78%
1 Month
-10.04%
3 Months
-0.29%
6 Months
-15.37%
1 Year
35.97%
3 Years
79.70%
5 Years
1 060.92%
10 Years
-

TickerPriceChg.Chg.%
BGNE316.93-4.8000-1.49
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
ValuationValueIndustryS&P 500US Markets
-24.30
7.66
37.16
605.70
-41.60
-9.24
7.67
43.34
26.44B
Forward PE-26.09
PEG-0.66
Financial StrengthValueIndustryS&P 500US Markets
4.40
4.60
0.05
0.16
-
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-55.80
-140.70
-136.80
-2 453.40
-94.67
RevenueValueIndustryS&P 500US Markets
797.05M
8.63
218.50
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-3.350.69120.60
Q04 2020-4.03-5.20-29.03
Q03 2020-4.11-4.81-17.03
Q02 2020-5.02-4.3114.14
Q01 2020-4.83-4.702.69
Q04 2019-4.84-6.39-32.02
Q03 2019-3.55-5.11-43.94
Q02 2019-3.01-1.4352.49
Earnings Per EndEstimateRevision %Trend
6/2021 QR-2.935.48Positive
9/2021 QR-4.36-26.38Negative
12/2021 FY-10.6433.91Positive
12/2022 FY-12.492.73Positive
Next Report Date5th Aug 2021
Estimated EPS Next Report-3.82
Estimates Count3
EPS Growth Next 5 Years %37.00
Volume Overview
Volume304.47K
Shares Outstanding92.38M
Trades Count5.44K
Dollar Volume148.08M
Avg. Volume245.43K
Avg. Weekly Volume235.00K
Avg. Monthly Volume222.21K
Avg. Quarterly Volume178.46K

BeiGene Ltd. (NASDAQ: BGNE) stock closed at 316.93 per share at the end of the most recent trading day (a -1.49% change compared to the prior day closing price) with a volume of 305.41K shares and market capitalization of 29.28B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5300 people. BeiGene Ltd. CEO is John V. Oyler.

The one-year performance of BeiGene Ltd. stock is 35.97%, while year-to-date (YTD) performance is 22.66%. BGNE stock has a five-year performance of 1060.92%. Its 52-week range is between 204.17 and 388.97, which gives BGNE stock a 52-week price range ratio of 61.02%

BeiGene Ltd. currently has a PE ratio of -24.30, a price-to-book (PB) ratio of 7.66, a price-to-sale (PS) ratio of 37.16, a price to cashflow ratio of 605.70, a PEG ratio of 2.32, a ROA of -22.99%, a ROC of -30.10% and a ROE of -33.36%. The company’s profit margin is -94.67%, its EBITDA margin is -136.80%, and its revenue ttm is $797.05 Million , which makes it $8.63 revenue per share.

Of the last four earnings reports from BeiGene Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-3.82 for the next earnings report. BeiGene Ltd.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for BeiGene Ltd. is Moderate Buy (1.77), with a target price of $399.66, which is +26.10% compared to the current price. The earnings rating for BeiGene Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BeiGene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BeiGene Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.53, ATR14 : 12.48, CCI20 : -93.12, Chaikin Money Flow : -0.12, MACD : -6.04, Money Flow Index : 34.45, ROC : 0.58, RSI : 42.79, STOCH (14,3) : 36.92, STOCH RSI : 0.63, UO : 43.99, Williams %R : -63.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BeiGene Ltd. in the last 12-months were: Howard Liang (Option Excercise at a value of $702 650), John V. Oyler (Sold 233 800 shares of value $5 740 188 ), Xiaodong Wang (Option Excercise at a value of $5 734)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (54.55 %)
7 (58.33 %)
8 (61.54 %)
Moderate Buy
1 (9.09 %)
1 (8.33 %)
1 (7.69 %)
Hold
4 (36.36 %)
4 (33.33 %)
4 (30.77 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.77
Moderate Buy
1.71
Moderate Buy
1.65

BeiGene Ltd.

BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.

CEO: John V. Oyler

Telephone: +1 345 949-4123

Address: c/o Mourant Governance Services (Cayman) Limited, Grand Cayman KY1-1108, , KY

Number of employees: 5 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

86%14%

Bearish Bullish

63%37%

Bearish Bullish

64%36%

News

Stocktwits